Skip to main
ORGO

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings is a regenerative medicine company with a focus on the advanced wound care and surgical & sports medicine markets. With a projected revenue increase for the next few years and a diverse product portfolio, the company is well positioned for growth. Though there may be initial dips in revenue due to reimbursement policy changes, the company is expected to recover and their stock is currently undervalued compared to their competitors.

Bears say

Organogenesis Holdings is facing significant challenges in the wound care market due to reimbursement uncertainties caused by CMS decisions in 2026. This has resulted in a decline in stock value and limited potential for upward revisions and multiple expansion. The company has a potential growth opportunity with its ReNu product, but the uncertainty surrounding FDA approval and commercialization makes it difficult to underwrite. Additionally, CMS changes have had a significant impact on the company’s revenue and profitability, with a potential hit to EBITDA for the first time in several years. However, ORGO remains one of the leaders in the regenerative medicine wound care market, with FDA approved products and a potential TAM of over $10 billion. ORGO also faces risks such as potential dilution from future capital raises and failure to secure FDA approval for ReNu. With limited visibility into its business and mixed clinical data, it is currently difficult to accurately forecast the impact of these changes on ORGO’s revenue and profitability.

Organogenesis Holdings (ORGO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 2 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.